As of 2026-03-29 19:39 UTC, the UK's clinical-trials reform should no longer be read as a future policy announcement. The law is signed, the commencement date is fixed at 2026-04-28, and the practical risk has shifted to transition design.[1] For sponsors, CROs, and NHS research teams, the hard part is not memorising the slogan about a "once-in-20-years rewrite." It is understanding that the switchover is not one clean cut. Approval route, modification route, transparency duties, good-clinical-practice rules, and pharmacovigilance do not all move on the same logic at the same moment.[1][2][3][4][5]

That matters because a bad internal assumption here can create avoidable delay. A team that treats April 28 as a simple old-rules/new-rules divide can mis-file an application, miss a publication duty, or discover too late that a trial still authorised under the 2004 framework has already inherited parts of the amended regime.[2][3][5]

Image context: the header photo shows 10 South Colonnade in Canary Wharf, the London office address listed by MHRA. It is the right image because this story is now about operational transition inside the UK's clinical-trials system rather than about laboratory science in the abstract.[7][8]

What actually changes on 28 April 2026

MHRA's April 2025 announcement established the sequence. The amended clinical-trials regulations were signed into law on 2025-04-11, but a technical issue in the legislation platform required the statutory instrument to be re-signed, which shifted commencement to 2026-04-28.[1] The same announcement also confirmed that two existing operating features move from practice into law: the Combined Review pathway and the notification scheme for some initial applications and amendments.[1]

The new application guidance then turns those legal changes into a sponsor workflow. From 2026-04-28, applications are expected to run through IRAS, undergo validation, and receive the outcome of those validation checks within 7 calendar days.[2] HRA's approvals guidance says the licensing authority and the research ethics committee then assess the application in parallel, with an initial review completed within a maximum of 30 calendar days.[4] If further information is requested, the sponsor gets 60 calendar days to answer, and the final decision follows within 10 calendar days of receiving a complete response.[2][4]

That timing is not only an aspiration. MHRA's own performance page says the agency's median time to a first decision on initial applications was 29 days in the latest reported period.[6] The policy promise, in other words, has already become an operating benchmark against which sponsors can measure whether the new regime is behaving as advertised.

Why the transition is a split file, not a single switch

The transition guidance is where the story becomes more complicated and more useful. The first dividing line is the initial application date. If the first application for approval is submitted before 2026-04-28, the trial remains under the old regulations for that initial approval path. If the first application is submitted on or after 2026-04-28, it enters the amended regime.[3]

But that is only the first line, not the whole map.

The second dividing line is the modification date. MHRA's transition guidance says that substantial modifications submitted on or after 2026-04-28 are handled under the amended rules, even if the trial itself was initially authorised under the old framework.[3] That creates an immediate operational consequence: sponsors with ongoing trials cannot assume that "old trial" means "old paperwork" for the rest of the study. Their modification queue becomes part of the April transition whether they want it to or not.[3]

The third dividing line is the trial end date. HRA's transparency guidance says sponsors must publish summary results for clinical trials within 12 months of the end of the trial, and this applies not only to trials approved under the new regulations, but also to older-regime trials that end on or after 2026-04-28.[5] Participant-facing accessible summaries are narrower: the requirement applies to trials approved under the amended rules, not to legacy trials that merely continue past the changeover.[3][5]

Then there is the fourth line: conduct and safety rules. MHRA's transition page says the amended good clinical practice requirements in Part 4 will apply from 2026-04-28 to trials under both the old and new regulations, with some exceptions such as the new trial-master-file retention rule.[3] Pharmacovigilance is also not a pure clean break. The amended Part 5 safety rules become the default from 2026-04-28, but sponsors of legacy trials can ask to remain temporarily on the old pharmacovigilance rules until their first annual safety report falls due under the old regime.[3]

That is why the most accurate way to describe April is not "new rules begin." A better description is that the UK clinical-trials system enters a dual-track period in which different obligations attach according to different clocks.

Where sponsors are most likely to get caught

1. Filing strategy gets left too late

There is now a live strategic difference between filing before and after 2026-04-28.[2][3] Teams close to submission need to decide whether they want the old-rule initial approval path or whether they are ready to file directly into the amended system. That choice affects document preparation, IRAS handling, and the review assumptions built into the project plan.[2][3][4]

2. Ongoing trials are treated as untouched by the reform

That assumption is too broad. Even where the initial authorisation stays under the old regime, post-April modifications, parts of good clinical practice, the pharmacovigilance default, and the 12-month summary-results publication duty can still move under the amended framework.[3][5] The risk here is not abstract non-compliance. It is fragmented SOP ownership, with operations, safety, and transparency workstreams following different internal rulebooks for the same study.

3. Teams focus on approval speed and forget transparency

The reform package is designed partly to speed approvals and reduce duplication, but the transparency layer is not decorative.[1][4][5] Sponsors must still think about public registration and results reporting early, because the publication clock is keyed to trial end dates and the accessible-summary requirement now sits inside the new-rule package.[2][3][5] A company that wins time at the front of the study and loses control of publication duties at the back has not really managed the transition well.

What a serious next-30-day checklist looks like

The cleanest read on the file is straightforward. The UK's clinical-trials reform is now past the headline stage. As of late March 2026, it is a sponsor-transition test built out of overlapping dates, not a ceremonial launch-day switch. The winners will be the teams that treat April 28 as a map of interacting deadlines and rule layers. The losers will be the teams that treat it as one date and one decision.[1][2][3][4][5][6]

Sources

  1. MHRA, "Clinical trials regulations signed into law" (published 11 April 2025; post-publication note updating commencement to 28 April 2026).
  2. MHRA, "Clinical trials for medicines: apply for approval in the UK" (updated 9 March 2026).
  3. MHRA, "Clinical trials transition to the new regulations".
  4. Health Research Authority, "The approvals process for clinical trials".
  5. Health Research Authority, "Publishing research findings".
  6. MHRA, "MHRA performance data".
  7. MHRA, "Access and opening" page listing 10 South Colonnade, Canary Wharf, London, E14 4PU.
  8. Wikimedia Commons, "File:10 South Colonnade and Canary Wharf DLR (south side).jpg".